Khanh K. Nguyen
Research Subjects
Research Interests
Khanh K. Nguyen has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Huy A. Nguyen
San Jose Gastroenterology
27 shared publications - Huy N. Trinh
Pacific Health Foundation
27 shared publications Ruel T. Garcia
22 shared publications- Mindie H. Nguyen
Division of Gastroenterology and Hepatology Department of Medicine Stanford University Medical Center Palo Alto California USA
20 shared publications - Brian S. Levitt
San Jose Gastroenterology
16 shared publications - Nghiem B. Ha
Stanford University Medical Center
9 shared publications
Latest Publications
- 1 March 2013
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 25 (3) , 338-343
Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice
Data from registration trials with highly selective patients have shown that hepatitis B envelope antigen (HBeAg)-positive patients with chronic hepatitis B respond well to entecavir (ETV) 0.5 mg daily, with an HBeAg seroconversion rate of 21% at 12 months. However, there are varying data on the treatment outcomes of ETV 0.5 mg daily in routine clinical settings, with seroconversion rates at 12 months ranging from 8 to 48% in studies limited to 44–90 patients from centers in Asia, Europe, and South America. In the present study, we examined long-term treatment efficacy and tolerability in 136 consecutive treatment-naive HBeAg-positive chronic hepatitis B patients treated between January 2005 and January 2011 with ETV 0.5 mg daily at community clinics and tertiary centers in the USA. The primary study end point was HBeAg seroconversion. Sixty-one percent of HBeAg-positive patients were men, mean age 39±12 years, median hepatitis B virus DNA 7.48 (3.7–9.8) log10 IU/ml, median alanine aminotransferase 67 (14–1077) U/l, and median treatment duration 18 (6–60) months. At months 12, 24, and 36, complete viral suppression rates were 41, 66, and 85% and HBeAg seroconversion rates were 4.8, 20, and 30%, respectively. No patients experienced adverse events or developed genotypic resistance to ETV. In clinical settings, ETV is highly tolerable and potent at suppressing hepatitis B viremia; however, the rates of HBeAg seroconversion appear to be much lower than those reported, highlighting the importance of appropriate counseling and planning for long-term therapy.
- 1 March 2013
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 25 (3) , 338-343
Low hepatitis B envelope antigen seroconversion rate in chronic hepatitis B patients on long-term entecavir 0.5 mg daily in routine clinical practice
Data from registration trials with highly selective patients have shown that hepatitis B envelope antigen (HBeAg)-positive patients with chronic hepatitis B respond well to entecavir (ETV) 0.5 mg daily, with an HBeAg seroconversion rate of 21% at 12 months. However, there are varying data on the treatment outcomes of ETV 0.5 mg daily in routine clinical settings, with seroconversion rates at 12 months ranging from 8 to 48% in studies limited to 44–90 patients from centers in Asia, Europe, and South America. In the present study, we examined long-term treatment efficacy and tolerability in 136 consecutive treatment-naive HBeAg-positive chronic hepatitis B patients treated between January 2005 and January 2011 with ETV 0.5 mg daily at community clinics and tertiary centers in the USA. The primary study end point was HBeAg seroconversion. Sixty-one percent of HBeAg-positive patients were men, mean age 39±12 years, median hepatitis B virus DNA 7.48 (3.7–9.8) log10 IU/ml, median alanine aminotransferase 67 (14–1077) U/l, and median treatment duration 18 (6–60) months. At months 12, 24, and 36, complete viral suppression rates were 41, 66, and 85% and HBeAg seroconversion rates were 4.8, 20, and 30%, respectively. No patients experienced adverse events or developed genotypic resistance to ETV. In clinical settings, ETV is highly tolerable and potent at suppressing hepatitis B viremia; however, the rates of HBeAg seroconversion appear to be much lower than those reported, highlighting the importance of appropriate counseling and planning for long-term therapy.
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1043 Outcomes of Oral Antiviral Treatment for Chronic Hepatitis B (CHB) in Routine Clinical Practice
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1043 Outcomes of Oral Antiviral Treatment for Chronic Hepatitis B (CHB) in Routine Clinical Practice
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1087 Less Established Risk Factors are Common in Asian Americans With Hepatitis C Virus: A Case-Control Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1087 Less Established Risk Factors are Common in Asian Americans With Hepatitis C Virus: A Case-Control Study
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1003 High Prevalence of Hepatitis C Virus in Ethnically Diverse Community Patients With Non-Liver Related Gastrointestinal Complaints
- 1 May 2012
- Published by Elsevier in Gastroenterology
- Vol. 142 (5)
Sa1003 High Prevalence of Hepatitis C Virus in Ethnically Diverse Community Patients With Non-Liver Related Gastrointestinal Complaints
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
High Rate of Recurrent Hepatitis B Viremia Following Treatment-Induced Hepatitis B E Antigen (HBeAg) Seroconversion
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
High Rate of Recurrent Hepatitis B Viremia Following Treatment-Induced Hepatitis B E Antigen (HBeAg) Seroconversion
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Rapid Complete Viral Suppression (CVS) With Entecavir (ETV) in Adefovir (ADV)-Experienced Patients: Interim Report for a Multicenter Study
- 1 May 2011
- Published by Elsevier in Gastroenterology
- Vol. 140 (5)
Rapid Complete Viral Suppression (CVS) With Entecavir (ETV) in Adefovir (ADV)-Experienced Patients: Interim Report for a Multicenter Study